key: cord-0846510-ptk2n5z4
authors: Guimarães, Lara; Rossini, Caio V.T.; Lameu, Claudiana
title: Implications of SARS-Cov-2 infection on eNOS and iNOS activity: consequences for the respiratory and vascular systems
date: 2021-04-06
journal: Nitric Oxide
DOI: 10.1016/j.niox.2021.04.003
sha: daa3ec441ba47cd97f56eaf4d696173c81973dca
doc_id: 846510
cord_uid: ptk2n5z4

Symptoms of COVID-19 range from asymptomatic/mild symptoms to severe illness and death, consequence of an excessive inflammatory process triggered by SARS-CoV-2 infection. The diffuse inflammation leads to endothelium dysfunction in pulmonary blood vessels, uncoupling eNOS activity, lowering NO production, causing pulmonary physiological alterations and coagulopathy. On the other hand, iNOS activity is increased, which may be advantageous for host defense, once NO plays antiviral effects. However, overproduction of NO may be deleterious, generating a pro-inflammatory effect. In this review, we discussed the role of endogenous NO as a protective or deleterious agent of the respiratory and vascular systems, the most affected in COVID-19 patients, focusing on eNOS and iNOS roles. We also reviewed the currently available NO therapies and pointed out possible alternative treatments targeting NO metabolism, which could help mitigate health crises in the present and future CoV’s spillovers.

At the end of 2019, a new coronavirus (CoV), the severe acute respiratory syndrome (SARS)-CoV-2 emerged in Wuhan, China [1] . SARS-CoV-2 is the causative virus of coronavirus disease 2019 (COVID- 19) , whose symptoms range from asymptomatic to severe respiratory failure, leading patients to hospitalization and even to death [2] . Almost a year later, approximately 50 million cases and more than 1.2 million deaths were reported worldwide [3] .

Although seven known CoVs have crossed the species barrier and are endemic in humans, CoVs are broadly distributed in wildlife [4] . Virological surveillance of wild animals detected a variety of CoVs in mammals and birds [5] [6] [7] [8] . The manifold reports detecting numerous CoVs in animals, coupled with the ongoing and pre-existed spillovers of coronavirus in humans, indicate that future zoonotic transmission events may occur. Since the first SARS-CoV outbreak in 2002, several attempts have being made to develop strategies to fight these viruses, despite that, there are no effective therapeutic or vaccine options against human-infecting CoVs [9] [10] [11] [12] .

In the light of the new CoV outbreak, researchers around the world are making a task force to develop therapeutic strategies, targeting on the virus itself and the disease caused by the SARS-CoV-2.

Although some infected individuals have no symptoms, others report from common cold to severe respiratory failure, such as acute respiratory distress syndrome (ARDS), with multiple organ failure, as a consequence of an excessive inflammatory process triggered by SARS-CoV-2 infection [13] . The diffuse inflammation causes pulmonary physiology damage, and also endothelial disfunction and disturbances in nitric oxide (NO) metabolism, which activate coagulation and thrombin generation leading to thrombosis and pulmonary embolism observed in severe COVID-19 patients [14] . Attempting to find an immediate solution for COVID-19, approved drugs by the Food and Drug Administration (FDA) and similar agencies to treat other diseases are being investigated [15] [16] [17] . Nevertheless, there is no effective treatment for COVID-19, the strategies are to try minimizing the chances of hospitalization in the intensive care unit and to avoid invasive procedures like extracorporeal membrane oxygenation (ECMO) to oxygenate the lungs [17] .

In this sense, inhaled NO, a non-invasive method, has been investigated to treat COVID-19 and reduce the need for invasive mechanical ventilation. In addition to being a pulmonary vasodilator, NO can act as an anti-inflammatory and antithrombotic agent. NO donors and NO gas also showed antibacterial and antiviral properties in in vitro studies and early clinical investigations [18] . However, excessive exposure at high levels of NO can be deleterious to the organism; cells in pro-oxidative state J o u r n a l P r e -p r o o f consolidation since early phase of the disease. Linear opacities, crazy-paving pattern, reverse halo sign and other alterations were observed in patients in the late phase. Also, lung tissue involvement is not homogeneous, which means that patients have different parts of the lungs compromised [34] [35] [36] . These findings confirm that the virus causes physiopathological alterations in lung parenchyma and pulmonary vascular structure, which induce ARDS.

ARDS patients are divided into three exclusive categories (mild, moderate, and severe) based on degree of hypoxemia, which is primarily caused by ventilation-perfusion rate (V/Q) mismatch, an outcome of pulmonary vascular changes [33, 37] . Dual-energy CT imaging of COVID-19 pneumonia has shown a higher perfusion in areas with opacities and consolidation, lowering the V/Q and causing venous admixture [38] . In healthy individuals, hypoxemia induces vasoconstriction in intrapulmonary arteries to reduce desaturated blood flow through underventilated areas in the lungs, redirecting it to better-oxygenated lung segments [39, 40] . Inversely, high blood pressure in these specific ventilated areas of the lungs promotes shear stress, which increases eNOS activity and, hence, NO-induced vasodilatation [41] (Fig. 1A) . However, ARDS diffuse inflammatory process triggers a vasodilatation cascade in non-ventilated parts of the lungs (deregulating hypoxic vasoconstrictive mechanisms) and vasoconstriction in ventilated areas. The imbalance between vasoconstricting and vasodilating pathways leads to endothelium dysfunction (Fig. 1B) [38, 39, 42] . In individuals with intact endothelium, alveolar hypoxia induces vasoconstriction in intrapulmonary arteries, redirecting blood flow to well ventilated areas. The blood pressure in arteries near ventilated alveoli rises, which in turn promotes shear stress, induces eNOS activity and increases the concentration of endothelium-derived vasodilators, like NO, inhibiting HPV and promoting widening of vessel diameter. This regulation causes the blood to flow in direction of well-ventilated areas, improving V/Q [39] [40] [41] . (B) In ARDS patients, the diffuse inflammation causes endothelial dysfunction in intrapulmonary arteries, causing reduction of HPV. In this situation, the production of endothelium-derived vasoconstrictors (endothelin and thromboxane) is disrupted, causing relaxation of vessel walls in underventilated areas. Once the blood flow is not redirected to well ventilated areas and the activation of eNOS by shear does not occur, inhibiting the production of endothelium-derived vasodilators. These events may cause redirection of blood flow to areas were gas exchange is compromised, worsening V/Q [38, 42] .

The diffuse inflammation in lung tissue stimulates phenotypic changes in blood vessel endothelial cells, due to injury and increased arginase activity, lowering L-arginine availability, which leads to eNOS uncoupling, increasing RNOS production and contributing to endothelial dysfunction [28, 30, 43, 44] .

These abnormalities together suggest an intrapulmonary shunt to areas where gas exchange is compromised, worsening V/Q mismatch, causing hypoxemia, increased vascular pulmonary resistance and pulmonary hypertension [45] . In an attempt to reverse severe ARDS symptoms and prevent progression in COVID-19 early phase patients, many therapeutic options that modulate respiratory physiology are being proposed, like plateau airway pressure, neuromuscular blockade, extracorporeal membrane oxygenation and inhaled NO [46] .

Up to now, inhaled NO is under study in dozens of CoV-related clinical trials [47] These interventional studies not only focus on reversing virus burden and respiratory failure in patients on mechanical ventilation, but also treat and prevent progression in patients with mild and moderate J o u r n a l P r e -p r o o f disease and as a preventive option for healthcare providers [47] . Under physiological conditions, blood vessel endothelial cells produce NO, which diffuses into the smooth muscle layer and promotes relaxation and vasodilation through physiological activation of NO-sensitive guanylyl cyclase forming cGMP from GTP. cGMP plays a key role in maintaining the physiological tissue homeostasis, regulating the activity of different targets downstream, such as cGMP-regulated ion channels, cGMP-dependent phosphodiesterases and cGMP-dependent protein kinase (PKG) [48] . After activation by cGMP, PKG phosphorylates myosin light chain phosphatase, which in turn dephosphorylates regulatory light chain (RLC) of myosin, promoting relaxation. cGMP also decreases Ca 2+ cytosolic concentration, inhibiting the Ca 2+ /calmodulin-dependent protein kinase, myosin light chain kinase, activity, therefore preventing RLC phosphorylation and contributing to smooth muscle relaxation [49] . Given that eNOS is uncoupled in patients with blood vessel endothelial dysfunction, inhaled NO has been used as therapeutic option to replace the endogenous NO activity in patients with several pulmonary complications, including ARDS.

As inhaled NO acts selectively, only inducing vasodilatation in lung areas where ventilation is not compromised, it can improve V/Q mismatch [50, 51] .

Nevertheless, inhaled NO application remains debatable. Inhaled NO benefits on oxygenation is transitory and does not appear to be associated with increased survival. Likewise, most ARDS patients die from multiple organ failure rather than hypoxaemia [52] . Moreover, prolonged exposure to inhaled NO can cause sensitization, lowering the oxygenation benefit while exposing these patients to oxidative toxic damage, reducing its benefits [53, 54] . Renal function in patients receiving inhaled NO treatment can also be compromised, increasing the need for renal replacement therapy [55] . In order to avoid complications, controlled therapies to regulate the metabolism of NO should be investigated, including an allosteric ASS activator, the step-limiting enzyme of NO-citrulline cycle [19, 56] .

Besides the deleterious effects of SARS-CoV-2-induced diffuse inflammation in pulmonary physiology and oxygen saturation, such virus can also induce coagulopathy. Autopsies from COVID-19positive patients have shown diffuse alveolar damage, widespread lung vascular thrombosis, microvascular thromboembolic, capillary congestion and deep venous thrombosis [57] . Thus, high ddimer levels in the blood, a coagulopathy marker, are associated with increased mortality in COVID-19 patients. Indeed, pulmonary embolism was the direct cause of death in some patients [57] [58] [59] . Multiorgan failure, observed in severe COVID-19 cases, has been linked with diffuse intravascular coagulation J o u r n a l P r e -p r o o f and large-vessel thrombosis [58, 60, 61] . Therefore, National Institute of Health treatment guideline for COVID-19 patients recommends anticoagulant therapy as prophylaxis for hospitalised individuals [62] .

In the COVID-19, several factors contribute for coagulopathy. The inflammatory response, generated by virus infection, leads to the activation of coagulation cascade, thrombin generation and fibrinolysis shutdown [63] [64] [65] . Hypoxemia can also contribute to coagulopathy, increasing blood viscosity and triggering the release of hypoxia-inducible transcription factors, that in turn influence the coagulation and fibrinolysis cascades [66] . Furthermore, endothelial injury and dysfunction caused by pro-inflammatory cytokines and tropism of the virus for ACE2 receptors, decrease the bioavailability of NO and trigger venous thromboembolism and disruption of natural antithrombotic state [67] . Also, eNOS uncoupling due to low L-arginine levels, impairs NO production or bioavailability in ARDS patients, which induces vasoconstriction and can lead to arterial and venous thrombosis [68] . On the other hand, under physiological conditions, eNOS-produced NO in the intact endothelium is released and then the NO/cGMP/PKG signaling pathway induces vasodilatation, inhibits platelet adhesion and aggregation and prevents smooth muscle cell proliferation, hindering thrombus formation [68] . Nevertheless, there is no clinically available NO therapy that addresses endothelial dysfunction directly, which could prevent thrombosis in COVID-19 patients [68, 69] .

Several therapeutic strategies with NO-enhancing and -releasing agents have been studied to develop new antithrombotic drugs [68] ; even so, NO is not under studies to prevent coagulopathy in COVID-19.

NO is a key molecule in the regulation of immune response to pathogens [70] [71] [72] [73] [74] . Mainly, iNOSsynthesized NO is an important immunoregulatory mediator of the host's immune system against infectious organisms, and acts as a toxic agent. Futhermore, NO can regulate cellular function, growth and death of immune cells, such as macrophages, neutrophils, T cells and natural killers (NK) cells [25] .

Although macrophages are the main NO producers in response to pathogens [75] [76] [77] , many cells express iNOS, including fibroblasts, hepatocytes [78] , endothelial and epithelial cells, keratinocytes and chondrocytes [79, 80] antigen-presenting cells [81] and NK cells [25, 82] . iNOS expression is induced by several agents, including microbial lipopolysaccharides and cytokines [83] [84] [85] . Once expressed, unlike eNOS and nNOS, iNOS is continuously active. Therefore, iNOS provides continuous high concentrations J o u r n a l P r e -p r o o f of NO to chemically neutralize invading pathogens, and this level of synthesis is sustained for hours or days, depending on how long the enzyme is present in cells or tissue [25] .

NO has several advantages as an antiviral agent, despite that, there are few studies investigating its potential therapeutic in viral infections. Firstly, it can easily pass through cell membranes to neighboring cells, as well as to viruses, not requiring a receptor [86] . Also, NO acts on a variety of viral targets, inhibiting viral replication; and cell specificity depends on its concentration, chemical reactivity, proximity of target cells and the way that target cells are designed to respond [25] . Finally, the NO effect is independent of the immune recognition of the infected cell, in contrast to antiviral lymphocytes. Such effect may be important in virus-infected cells where the major histocompatibility complex, essential for the adaptive immune system, is limited and/or sub regulated [86] . Given the highly reactive nature of NO, its antiviral effects are probably mediated by reactions with multiple cellular and viral targets which may be advantageous for host defense because it will limit the capacity of viruses to develop resistance.

Studies have shown that the NO antiviral effects are provided by NO donors [87] [88] [89] [90] [91] or by iNOS directly activated by cytokines [83] [84] [85] . Rimmelzwaan et al. [92] demonstrated that influenza A virus replication in MDCK cells was severely impaired by NO generating compound, S -nitroso-Nacetylpenicillamine (SNAP). Reduction of infected cells and virus production proved to correlate with reduction of viral protein activity and viral RNA synthesis ( Fig. 2A) , indicating that NO affects an early stage in the replication cycle of influenza viruses. This same group hypothesizes that iNOS-synthesized NO in airways epithelial cells, induced by cytokines synthesized after virus infection [93, 94] , provides an antiviral effect in these cells. Likewise, exposure to NO demonstrated dose-dependent antiviral effects in cells infected with influenza A, B and H1N1 [95] . Additionally, it has been reported that peroxynitrite, an intermediate product formed by the reaction of NO with superoxide, inhibits the entry of RNA of some viruses into host cells [96] .

With the new CoV global outbreak, the search for effective antivirals against SARS-CoV-2 is an important undertaking. Interestingly, inhibition of SARS-CoV replication cycle in vitro was reported with NO donors by two distinct mechanisms, by affecting spike (S) protein and ACE2 fusion (Fig. 2B) or reduction of viral RNA load in early stages of replication (Fig. 2C) [73] . Although its antiviral effects against SARS-CoV-2 is not yet elucidated, evidence shows that NO has a great potential. We hypothesize that metabolic enhancement of NO production and NO bioavailability through complex interventions can partially reverse deleterious physiological conditions associated with viral infection and unregulated pro-inflammatory processes.

J o u r n a l P r e -p r o o f 

Although NO plays a protective role in viral infection, it can also contribute to immunopathology of COVID-19. NO generation is a tightly regulated process; the pathophysiological conditions that deregulate it lead to reactive oxygen species (ROS) generation [29, 101, 102] . Excessive ROS produced by the endothelium and epithelium, as well as by leukocytes, play an important role in ARDS progression and lung damage. ROS positively regulate the expression of proinflammatory cytokines and adhesion molecules, causing endothelial and epithelial dysfunctions, along with increasing oxidative stress in pulmonary duct tissues and airways, further altering the inflammatory state [29, 103, 104] . Throughout ARDS process, lung cells release large amounts of inflammatory factors that increase iNOS synthesis in alveolar macrophages, neutrophils and bronchial epithelium, providing abundant amounts of NO for release into lung tissues [105, 106] . Moreover, airway stress can induce bronchial obstruction and worsen inflammation in ARDS patients, further inducing lung tissues to produce NO [107] .

Overproduction of NO leads to deleterious cell components damage when reacting with superoxide, and favors the formation of peroxynitrite that can nitrate and oxidize proteins, lipids and nucleotides [108] . In case of increased plasma NO levels, the reaction between NO and superoxide to form peroxynitrite becomes very fast, where the production rate is about three times higher than the rate of superoxide decomposition by superoxide dismutase [109] . Excessive peroxynitrite formation can lead to inhibition of mitochondrial respiration, protein dysfunction, depletion of cellular energy, damage to cell membranes and DNA [108] , in addition to contributing to resistance to anti-inflammatory drugs [110] . Although reactive nitrogen species (RNS) are more widely cited, both ROS and RNS are capable of interact with proteins, DNA or lipids by oxidation or nitrosation [111] .

NO-mediated oxidative stress is an important factor in the pathogenesis of lung injury. High levels of NO, represented by the increase of its stable metabolites, nitrate and nitrite, can intensify lipid peroxidation, cause necrosis and denaturation of pulmonary epithelial cells, aggravate inflammation and induce the onset of ARDS [112] . A clinical study reported high concentrations of the NO, nitrate and nitrite metabolites in the bronchoalveolar lavage, not only in ARDS patients, but also in patients at risk for ARDS, suggesting that the oxidative stress detected at the beginning of ARDS begins when patients are at risk, before the clinically defined syndrome is recognized [113] .

Since the first CoV outbreak in 2002, researchers have tried to find alternatives to deal with the health crises caused by the virus spillovers, however, there is still no vaccine or target therapies for J o u r n a l P r e -p r o o f SARS-CoV-like viruses [114] [115] [116] . Furthermore, the constant destruction of wildlife habitats is likely to cause bat-to-human spillovers, leading to another CoV outbreak. Likewise, researchers have foresaw the recent CoV outbreak years ago [11, 117] . Thereat, it is important not to only develop a vaccine but to understand the pathology caused by these viruses and develop therapies to treat the disease.

As discussed in the present article, disruption of NO physiology is closely related to the development of ARDS in COVID-19 patients. Nevertheless, NO production pathways are affected in a different manner. While NO production by eNOS is compromised, inducing alterations in lung parenchyma and coagulopathy, NO production by iNOS is increased in effort to fight the virus, however, this proinflammatory state can cause a deleterious effect, leading to lung injury. Inhaled NO has been used in ARDS patients in an attempt to mitigate pulmonary physiological alterations caused by eNOS uncoupling, but the transitory effects and possible oxidative toxic damage may weaken the use of this therapy. Here, we propose the investigation of therapies that promote NO production in a metabolic manner. Molecules that positively modulate the activity of ASS, a key enzyme in arginine metabolism, would increase arginine production, leading to eNOS recoupling and increasing NO metabolite production [56] . On the contrary, specific iNOS inhibitors should attenuate ARDS intrapulmonary pathologies [118] . In conclusion, therapeutic approaches that modulate NO metabolism should be considered for the prevention or treatment of severe cases of COVID-19. 

The genetic sequence, origin, and diagnosis of SARS-CoV-2

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Coronaviruses: An overview of their replication and pathogenesis

Coronaviruses Methods Protoc

Bovine-like coronaviruses in domestic and wild ruminants

Detection and characterisation of coronaviruses in migratory and non-migratory Australian wild birds

Avian Coronavirus in Wild Aquatic Birds

Detection of a Novel and Highly Divergent Coronavirus from Asian Leopard Cats and Chinese Ferret Badgers in Southern China

Further evidence for bats as the evolutionary source of middle east respiratory syndrome coronavirus

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavi

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase

Rapid repurposing of drugs for COVID-19

Chloroquine Action: Perspectives and Implications in Malaria and COVID-19

Treatment Guidelines Coronavirus Disease

Home nitric oxide therapy for COVID-19

L-Arginine signalling potential in the brain: The peripheral gets central

A novel functional beverage for COVID-19 and other conditions: Hypothesis and preliminary data, increased blood flow, and wound healing

NO-cGMP signaling and regenerative medicine involving stem cells

Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages

Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle

Brain nitric oxide production by a proline-rich decapeptide from Bothrops jararaca venom improves baroreflex sensitivity of spontaneously hypertensive rats

Nitric oxide in immunity and inflammation

The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations

Arginase 1: An unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury

Targeting arginase and nitric oxide metabolism in chronic airway diseases and their co-morbidities

ROS signaling in the pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)

Bothrops jararaca peptide with antihypertensive action normalizes endothelium dysfunction involved in physiopathology of Preeclampsia

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Comparison of Hospitalized Patients With ARDS Caused by

COVID-19 and H1N1

Acute respiratory distress syndrome: The Berlin definition

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

CT imaging changes of corona virus disease 2019(COVID-19): A multi-center study in Southwest China

Chest CT findings in coronavirus disease 2019

Management of COVID-19 Respiratory Distress

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT

The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels

Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine

Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure

Selective pulmonary vasodilation in acute respiratory distress syndrome

Inflammation-induced caveolin-1 and BMPRII depletion promotes endothelial dysfunction and TGF-β-driven pulmonary vascular remodeling

Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation

Pulmonary vascular dysfunction in ARDS

Treatment for severe acute respiratory distress syndrome from COVID-19

COVID-19 | Nitric Oxide related studies

NO activation of guanylyl cyclase

Ikebe, cGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylation of myosin phosphatase

Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults

Modulating cGMP to treat lung diseases

Effect of nitric oxide on oxygenation and mortality in acute lung injury: Systematic review and meta-analysis

Inhaled nitric oxide therapy in adults

Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: A prospective, randomized, controlled study

Inhaled nitric oxide and the risk of renal dysfunction in patients with acute respiratory distress syndrome: A propensity-matched cohort study

Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide. Role in arginine and nitrix oxide production

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Antithrombotic Therapy in Patients with COVID-19, COVID-19 Treat

Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study

Coagulation and sepsis

COVID-19 cytokine storm: the interplay between inflammation and coagulation

The stimulation of thrombosis by hypoxia

COVID-19 and its implications for thrombosis and anticoagulation

Nitric oxide-enhancing or -releasing agents as antithrombotic drugs

Endothelial cell control of thrombosis

Induction of nitric oxide synthase during Japanese encephalitis virus infection: Evidence of protective role

Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions

Palmitoylation-dependent protein sorting

Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus

S)NO signals: Translocation, regulation, and a consensus motif

Cloning and characterization of inducible nitric oxide synthase from mouse macrophages, Science (80-. )

The nitric oxide pathway provides innate antiviral in fibroblasts

Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis

Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes

Nitric oxide-A new endogenous immunomodulator

Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity

Nitric oxide and T helper cell immunity

Natural killer cells and nitric oxide

Concurrent production of interleukin-2, interleukin-10, and gamma interferon in the regional lymph nodes of mice with influenza pneumonia

Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo

Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells

The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases

Resistance to Murine Hepatitis Virus Strain 3 Is Dependent on Production of Nitric Oxide

Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication

Inhibition of viral replication by interferon-γ-induced nitric oxide synthase, Science (80-. )

Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo

Inhibition of vesicular stomatitis virus infection by nitric oxide

Inhibition of influenza virus replication by nitric oxide

A kinetic study of immune mediators in the lungs of mice infected with influenza A virus

Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense

Gaseous nitric oxide reduces influenza infectivity in vitro

Peroxynitrite inhibition of coxsackievirus infection by prevention of viral RNA entry

Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle

Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected

S-Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide

Coronavirus biology and replication: implications for SARS-CoV-2

Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep

Novel effects of nitric oxide

Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid

A new technique of bronchial microsampling and proteomic analysis of epithelial lining fluid in a rat model of acute lung injury

Evaluation of recruited lung volume at inspiratory plateau pressure with PEEP using bedside digital chest X-ray in patients with acute lung injury/ARDS

The role of intrapulmonary nitric oxide generation in the development of adult respiratory distress syndrome

High exhaled nitric oxide levels may predict bronchial reversibility in allergic children with asthma or rhinitis

Reactive nitrogen species and tyrosine nitration in the respiratory tract: Epiphenomena or a pathobiologic mechanism of disease?

Nitric oxide production and signaling in inflammation

Inflammatory mechanisms in patients with chronic obstructive pulmonary disease

The role of nitric oxide and reactive nitrogen species in experimental ARDS

Correlation between nitric oxide content in exhaled breath condensate and the severity of acute respiratory distress syndrome

Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome

Coronaviruses-drug discovery and therapeutic options

Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: Biology and therapeutic options

Bat-borne virus diversity, spillover and emergence

Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks -Implications for coronavirus vaccine development

The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury